NCT04279938 - A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCL | Biotech Hunter

Timeline

Start Date

September 30, 2018

Primary Completion Date

March 31, 2020

Study Completion Date

January 31, 2021

Conditions

Relapsed or Refractory Diffuse Large B-cell Lymphoma

Interventions

DRUG

Tinostamustinein

Tinostamustine80-120mg IV Q3W (dose to be determined in part 1) for 6 cycles

DRUG

Pembrolizumab

Pembrolizumab 200mg IV Q3W until disease progression or unacceptable toxicities (max. 2 years)

DRUG

Rituximab

Rituximab 375 mg/m2 IV Q3W for 6 cycles

Trial Locations (1)

The Royal Marsden NHS Foundation Trust, Sutton